[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-side-effects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-side-effects":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,84,115,144,162,180,199],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100567532","taste-alterations-study-100567532",false,"NCT06669416","Taste Alterations Study","Effects of Patient Education and Self-Management in Cancer Patients Who Experience Chemotherapy-Induced Taste Alterations","TAS","Inclusion Criteria:\n\n* Medical diagnosis of cancer with types limited to the top cancer types \\[Note: Cancer types that are rare will be excluded\\]\n* Initiating chemotherapy (first day\u002Ffirst cycle) at participating clinics\n* English speaking\u002Freading (without an interpreter)\n\nExclusion Criteria:\n\n* Substitute decision-maker (activated)\n* History of head\u002Fneck cancer or irradiation\n* Known genetic\u002Fmetabolic disorder impacting taste (preexisting dysgeusia)\n* Known eating disorder\n* Receiving enteral or parenteral nutrition (special nutritional needs)\n* Pregnant women (unique needs)\n* Patients with medical orders for end of life\u002Fhospice care","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The main questions it aims to answer are:\n\n1. Does completing a standard assessment increase the detection of chemotherapy induced taste changes compared with usual care (no assessment)? What TA are experienced? Are there any patterns in TA symptom occurrence based on age, sex, race\u002Fethnicity, cancer type, chemotherapy agent, etc.\n2. Do patients take action to deal with the TA? What strategies are used? Do patients in the intervention group use the assessments to select interventions?\n3. Do the interventions lessen TA symptoms and maintain food intake? Is the treatment (in-depth assessment and education) more effective in lessening the intensity of TA than usual care? Which level of assessment is needed to support symptom management to reduce symptom severity?\n\nParticipants will:\n\nComplete baseline assessment before starting their initial chemotherapy infusion (all patients) Participate in baseline patient education based on assigned intervention (usual care vs. treatment) Engage in TA management between chemotherapy infusion clinic visits based on education Visit the clinic for chemotherapy infusions as scheduled; Complete TA assessments and reporting based on intervention; Work with nurse coaches to answer questions and help with the intervention.\n\nComplete study data collection on the 4th chemotherapy cycle (but continue intervention) Complete final data collection at 6 months",[27,28],"Chemotherapy Side Effects","Taste, Altered",[30,31],"self-management","cluster randomized control trial","RECRUITING","2026-05-20",{"date":35,"type":36},"2026-05-22","ACTUAL",{"date":38,"type":36},"2024-12-01",{"date":40,"type":21},"2026-09",{"name":42,"class":43},"Wake Forest University Health Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":56,"conditions":57,"keywords":68,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":44},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":20,"type":21},[54,55],"PHASE2","PHASE3","This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[58,59,60,61,62,63,64,27,65,66,67],"Rectal Cancer","Total Neoadjuvant Treatment","Neoadjuvant Therapy","Radiotherapy","Chemotherapy","Organ Preservation","Radiotherapy Side Effect","Chemoradiotherapy","Low Anterior Resection Syndrome","Quality of Life",[69,59,70,61,62,65,63,64,71,72,73,74,66],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications","2026-05-06",{"date":77,"type":36},"2026-05-11",{"date":79,"type":36},"2025-01-06",{"date":81,"type":21},"2029-12-27",{"name":83,"class":43},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":44},"100571876","remote-physical-activity-programming-to-improve-outcomes-in-cancer-survivors-with-and-without-type-2-diabetes-100571876","NCT06725953","Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes","Cerebrovascular, Cognitive, Pro-Inflammatory, and Cardiometabolic Outcomes in Cancer Survivors With and Without Type II Diabetes Reporting Chemo-Brain: Baseline Differences and Impact of Activity","CICI-PA","Inclusion Criteria:\n\n1. ≥18 years old\n2. ability to speak\u002Fread English\n3. ability to provide informed consent\n4. underwent treatment within the last three years for a non-central nervous system-related cancer with said treatment having included chemotherapy\n5. self-reported cognitive difficulties following cancer treatment\n6. For CS+T2D: current T2D diagnosis as classified by a fasted blood glucose of ≥126 mg\u002FdL, 2-hour oral glucose tolerance test of ≥200 mg\u002FdL, HbA1c level of ≥6.5%, or use of medications to treat hyperglycemia (e.g., Metformin) or For CS: no current T2D diagnosis as classified by a fasted blood glucose \\\u003C100 mg\u002FdL, 2-hour oral glucose tolerance test \\\u003C140 mg\u002FdL, or HbA1c level of \\\u003C5.7%. Presence\u002Fabsence of T2D to be confirmed preferentially via physician's documentation\n7. own smartphone and\u002For computer with internet access\n8. willing to participate in the 12-week remotely-delivered PA program\n\nExclusion Criteria:\n\n1. reporting a Physical Activity Readiness Questionnaire (2017 PAR-Q) score that indicates PA may potentially be unsafe, unless the participant produces a signed doctor's note. We will define 2017 PAR-Q+ scores as indicating that PA may potentially be unsafe as responding \"Yes\" to any of the follow-up questions except \\[1\\] if the individual indicates that they have high blood pressure but subsequent responses indicate that they do not have problems keeping it under control and that their resting blood pressure is less than 160\u002F90 mmHg, and \\[2\\] if the individual indicates that they have a metabolic condition but subsequent responses indicate that they do not have problems controlling their blood sugar levels, do not any experience signs or symptoms of hypoglycemia, and do not have any signs of symptoms of listed diabetes complications)\n2. engaging in ≥75 min\u002Fweek of vigorous-intensity PA, ≥150 min\u002Fweek of moderate-intensity PA, or an equivalent combination of both over the last 3 months\n3. currently a prisoner, pregnant, or planning to become pregnant during study.",{"count":93,"type":21},38,[24],"The growing U.S. cancer survivor population is projected to hit 26M by 2040. Chemotherapy represents an effective cancer treatment but can diminish cancer survivors' quality of life-particularly cognitive function-through select pathophysiological processes. Research on chemotherapy-induced cognitive impairment (hereafter, 'chemo-brain') is therefore critical. Chemotherapy disrupts immune system function and antioxidant regulation, causing inflammatory molecule release and damaging the brain's blood vessels. The brain's vascular function and, possibly, its neurons, are subsequently impaired-likely contributing to chemo-brain. Type 2 diabetes (T2D), a common cancer survivor comorbidity, shares underlying pathophysiology with chemo-brain. T2D-related insulin resistance can precipitate repeated high blood sugar episodes which increase inflammatory molecule release. In individuals with T2D without cancer, negative relationships are observed between inflammatory molecule concentrations and the brain's vascular and\u002For cognitive function. Cancer survivors with T2D might thus have higher chemo-brain risk than those without T2D. Yet, more research must compare how the brain's vascular function, as well as cognitive, inflammatory, and cardiometabolic indices, differ between these groups. Physical activity (PA) counteracts chemo-brain's and T2D's pathophysiology, with higher PA\u002Ffitness resulting in better vascular function of the brain, lower inflammatory molecule concentrations, and improved insulin sensitivity. We are therefore conducting a 30-participant quasi-experimental pilot study in cancer survivors with (cases) and without (controls) T2D. We will first investigate between-group differences in the brain's vascular function as well as cognitive, inflammatory, cardiometabolic, and epigenetic outcomes. We will then examine between-group changes in these outcomes and select psychosocial metrics during a 12-week technology-based PA program-potentially further elucidating involved mechanisms.",[97,27],"Cancer Survivorship",[99,100,101,102,103,104,105],"Aerobic Physical Activity","Resistance Training","Wearable Devices","Smartphone Applications","Cancer Survivors","Chemo-Brain","Health Outcomes","2026-04-27",{"date":108,"type":36},"2026-05-01",{"date":110,"type":36},"2025-03-10",{"date":112,"type":21},"2027-02",{"name":114,"class":43},"University of Oklahoma",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":121,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":143},"100623491","phase-1-clinical-study-of-da-020-for-the-treatment-of-chemotherapy-induced-alopecia-100623491","NCT07397325","Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia","Inclusion Criteria:\n\n* Diagnosed with stage I or stage II breast cancer\n* Scheduled but not begun, at least 4 cycles of taxane and\u002For anthracycline-based chemotherapy.\n* Ages 18-65\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Resting blood pressure outside the range of 105-140\u002F 55-99\n* Uncontrolled or severe hypertension\n* Female pattern hair loss or hair loss disorder\n* Folliculitis\n* Scalp psoriasis\n* Seborrheic dermatitis\n* Inflammatory scalp conditions such as lichen planopillaris\n* Subjects wearing wigs prior to chemotherapy\n* Use of MAO inhibitors\n* Unable to provide consent or make allotted clinical visits","FEMALE","65 Years",{"count":124,"type":21},60,[126,54],"PHASE1","Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia",[129,27],"Chemotherapy Induced Alopecia",[129,131],"Chemotherapy Alopecia","NOT_YET_RECRUITING","2026-04-08",{"date":135,"type":36},"2026-04-13",{"date":137,"type":21},"2026-04-16",{"date":139,"type":21},"2026-12-07",{"name":141,"class":142},"Applied Biology, Inc.","INDUSTRY",2,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":150,"sex":121,"minAge":18,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":148,"conditions":155,"keywords":156,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":143},"100623876","early-phase-1-pharmacokinetic-study-of-da-020-100623876","NCT07402330","Pharmacokinetic Study of DA-020","Inclusion Criteria:\n\n* Healthy females, age 18-55\n* BMI: 18-30 kg\u002Fm²\n* Fitzpatrick Skin Types I-IV (to standardize absorption risk)\n* Scalp free from irritation, dermatologic disease, or damage\n* Able to refrain from using other topical scalp products\n\nExclusion Criteria:\n\n* History of cardiovascular disease, hypertension, or arrhythmia\n* Scalp infections, wounds, or significant hair loss\n* Recent use of medications that interfere with CYP enzymes or adrenergic systems\n* Known sensitivity to phenylephrine or ethanol\n* Positive drug screen or abnormal ECG at screening",true,"55 Years",{"count":124,"type":21},[154],"EARLY_PHASE1",[129,27],[129,131],{"date":135,"type":36},{"date":137,"type":21},{"date":160,"type":21},"2026-11-30",{"name":141,"class":142},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":150,"sex":121,"minAge":18,"maxAge":151,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":166,"conditions":170,"keywords":171,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100595545","early-phase-1-pharmacokinetic-study-of-topical-phenylephrine-100595545","NCT07033845","Pharmacokinetic Study of Topical Phenylephrine",{"count":168,"type":21},24,[154],[129,27],[129,131],"2025-09-30",{"date":174,"type":36},"2025-10-03",{"date":176,"type":36},"2025-06-30",{"date":178,"type":21},"2025-12-28",{"name":141,"class":142},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":121,"minAge":18,"maxAge":122,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":44},"100574689","phase-3-clinical-study-of-da-007-for-the-treatment-of-chemotherapy-induced-alopecia-100574689","NCT06762548","Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia",{"count":186,"type":21},140,[55],"Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia",[129,27],[129,131],"2025-05-22",{"date":193,"type":36},"2025-05-23",{"date":195,"type":21},"2025-10-10",{"date":197,"type":21},"2026-11-06",{"name":141,"class":142},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":221,"leadSponsor":223,"locationsCount":44},"100576923","the-impact-of-social-media-delivered-chemotherapy-side-effects-education-for-breast-cancer-patients-receiving-chemotherapy-100576923","NCT06791603","The Impact of Social Media-delivered Chemotherapy Side Effects Education for Breast Cancer Patients Receiving Chemotherapy","The Impact of Social Media-delivered Chemotherapy-related Side Effects Education for Breast Cancer Patients Receiving First Time Chemotherapy","Inclusion Criteria:\n\n* Breast cancer patients aged 18 or older undergoing their first chemotherapy.\n* Possess a smartphone and are able to watch videos on it.\n\nExclusion Criteria:\n\n* Unable to read or complete questionnaires in Chinese.\n* Cognitive impairments.\n* Pregnant women.",{"count":207,"type":21},100,[24],"The goal of this clinical trial is to learn if a standardized pharmacists-provided education module by social media can improve patients' knowledge of chemotherapy-related side effects. The main questions it aims to answer is:\n\n• Do patients who received a standardized pharmacists-provided education module by social media improve their knowledge of chemotherapy-related side effects? Researchers will compare standardized chemotherapy education +video (experimental group) versus chemotherapy handouts (control group).\n\nParticipants will:\n\n* Received standardized chemotherapy education + video or chemotherapy handouts at the first and second chemotherapy section.\n* Fill out a questionnaire for outcomes assessment.",[27,211,212],"Social Media","Education of Patients",[214,215,216],"pharmacist","chemotherapy education","social media","2025-01-22",{"date":219,"type":36},"2025-01-24",{"date":79,"type":36},{"date":222,"type":21},"2026-01-31",{"name":224,"class":43},"Taipei Medical University Shuang Ho Hospital"]